Deutsche Bank is reiterating its Buy rating on shares of Covance Inc. CVD and ICON plc ICLR.
“Key takeaways from the Annual Partnerships in Clinical Trials Conference: 1) Vendor consolidation amongst biopharma clients (from 10-to-15 to 2-to-4) and momentum towards strategic deals continues to accelerate,” Deutsche Bank writes.
“2) Emerging markets and increased penetration of R&D to drive industry growth. 3) Impact on OMs from pricing discounts to be largely offset by efficiency gains. Given our thesis, we reiterate our Buy rating of CVD (best leverage to strategic deals) and ICLR (GARP).”
ICON closed Monday at $21.48; Covance closed at $57.46.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in